All In Biotech

Drug Trial Radar · NCT06741098

A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis( KOA)

A Study to Evaluate the Safety, Tolerability and Efficacy of NCR100 Injection for the Treatment of Knee Osteoarthritis( KOA)

Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 162 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

162

Planned (sponsor's estimate)

Start

Feb 20, 2025

Primary completion

Nov 30, 2026

Study completion Nov 15, 2028

Sponsor

Sponsor type
Industry
Collaborators
Shanghai 6th People's Hospital
First posted
Dec 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It contains two parts dose-escalating, and blind random study in adult KOA subjects.

Conditions

  • Knee Osteoarthritis

Interventions

  • NCR100Biological

    Subjects will receive multiple intra-articular NCR100 injections.

  • 0.9% Normal salineOther

    Subjects will receive multiple intra-articular 0.9% Normal saline injections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity(DLT)Time frame: 4 weeks after first injection
  2. The Western Ontario and McMaster Universities osteoarthritis index(WOMAC)Time frame: 48 weeks after first injection

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.